NewAmsterdam Pharma (NAMS) Free Cash Flow (2023 - 2026)

NewAmsterdam Pharma has reported Free Cash Flow for 4 years, with the latest figure at -$30.6 million in Q1 2026.

• Quarterly Free Cash Flow rose 16.01% year-over-year to -$30.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$142.2 million (down 1.03% YoY) and the FY2025 annual result came in at -$148.0 million, up 7.04% from the prior year.
• Free Cash Flow advanced to -$30.6 million in Q1 2026 per NAMS's latest filing, from -$41.0 million in the prior quarter.
• Over five years, Free Cash Flow peaked at -$12.6 million in Q3 2024 and troughed at -$55.0 million in Q1 2024.
• A 4-year average of -$37.5 million and a median of -$37.0 million in 2024 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2024 and 2025: Free Cash Flow soared 73.23% in 2024, then sank 160.88% in 2025.
• Over 4 years, Free Cash Flow stood at -$33.1 million in 2023, then dropped by 13.32% to -$37.5 million in 2024, then decreased by 9.31% to -$41.0 million in 2025, then advanced by 25.22% to -$30.6 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$30.6 million, -$41.0 million, and -$32.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.